Comparative Efficacy and Safety of Once-Weekly Pegylated Recombinant Human Growth Hormone Versus Daily Growth Hormone Therapy in Children: A Systematic Review and Meta-Analysis.

For height SDS ( Figure 3 ), groups were comparable through 6 and 12 months (MD = −0.08 SDS, 95% CI −0.21 to 0.05 and MD = 0 SDS, −0.13 to 0.14, respectively), while a weakly significant advantage for PEG-rhGH appeared by 24 months (MD = 0.10 SDS, 95% CI 0.01 to 0.19).

also in 430 other papers